Show simple item record

dc.contributor.authorSlotman, B
dc.contributor.authorFaivre-Finn, Corinne
dc.contributor.authorvan Tinteren, H
dc.contributor.authorKeijser, A
dc.contributor.authorPraag, J
dc.contributor.authorKnegjens, J
dc.contributor.authorHatton, M
dc.contributor.authorvan Dam, I
dc.contributor.authorvan der Leest, A
dc.contributor.authorReymen, B
dc.contributor.authorStigt, J
dc.contributor.authorHaslett, Kate
dc.contributor.authorTripathi, D
dc.contributor.authorSmit, E
dc.contributor.authorSenan, S
dc.date.accessioned2017-07-13T10:58:59Z
dc.date.available2017-07-13T10:58:59Z
dc.date.issued2017-06
dc.identifier.citationWhich patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial. 2017, 108:150-153 Lung Canceren
dc.identifier.issn1872-8332
dc.identifier.pmid28625628
dc.identifier.doi10.1016/j.lungcan.2017.03.007
dc.identifier.urihttp://hdl.handle.net/10541/620450
dc.description.abstractIn ES-SCLC patients with residual intrathoracic disease after first-line chemotherapy, the addition of thoracic radiotherapy reduces the risk of intrathoracic recurrence, and improves 2-year survival. To identify patient subgroups for future trials investigating higher dose (extra)thoracic radiotherapy, we investigated the prognostic importance of number and sites of metastases in patients included in the CREST trial.
dc.language.isoenen
dc.rightsArchived with thanks to Lung cancer (Amsterdam, Netherlands)en
dc.titleWhich patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial.en
dc.typeArticleen
dc.contributor.departmentVU University Medical Center, Amsterdam, Netherlandsen
dc.identifier.journalLung Canceren
refterms.dateFOA2018-12-17T15:00:50Z
html.description.abstractIn ES-SCLC patients with residual intrathoracic disease after first-line chemotherapy, the addition of thoracic radiotherapy reduces the risk of intrathoracic recurrence, and improves 2-year survival. To identify patient subgroups for future trials investigating higher dose (extra)thoracic radiotherapy, we investigated the prognostic importance of number and sites of metastases in patients included in the CREST trial.


Files in this item

Thumbnail
Name:
Which patients with ES-SCLC are ...
Size:
605.6Kb
Format:
PDF
Description:
Open access full text article

This item appears in the following Collection(s)

Show simple item record